Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study will assess the effects of Bemnifosbuvir on cardiac repolarization in healthy Adult Subjects
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Bemnifosbuvir (BEM) therapeutic dose | Experimental | oral tablets |
|
| Bemnifosbuvir (BEM) supratherapeutic dose | Experimental | oral tablets |
|
| Placebo | Placebo Comparator | oral tablets |
|
| Moxifloxacin | Active Comparator | oral tablet |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Bemnifosbuvir (BEM) | Drug | A single dose of BEM will be administered. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Placebo-corrected (Δ) change-from-baseline QTc (ΔΔQTc). | C-QTc analysis | 24 hours prior to dosing thru 48 hours post dose |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Atea Study Site | Québec | Montreal, Quebec | Canada |
Not provided
| ID | Term |
|---|---|
| C000713067 | AT-511 |
| D000077266 | Moxifloxacin |
| ID | Term |
|---|---|
| D024841 | Fluoroquinolones |
| D042462 | 4-Quinolones |
| D015363 | Quinolones |
| D011804 | Quinolines |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Placebo | Drug | A single dose of matching placebo will be administered. |
|
| Moxifloxacin | Drug | A single dose of Moxifloxacin will be administered. |
|
| D006574 |
| Heterocyclic Compounds, 2-Ring |
| D000072471 | Heterocyclic Compounds, Fused-Ring |
| D006571 | Heterocyclic Compounds |